{"id":"matching-placebo-to-ramipril","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a placebo, this product contains no active pharmaceutical ingredient and is used as a control in clinical trials to compare against active Ramipril treatment. Ramipril itself works by inhibiting ACE, which prevents the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor, thereby reducing blood pressure and cardiac workload.","oneSentence":"This is a matching placebo formulation designed to mimic Ramipril, an ACE inhibitor that lowers blood pressure by blocking angiotensin-converting enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:05.773Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Clinical trial control for Ramipril studies in hypertension"},{"name":"Clinical trial control for Ramipril studies in heart failure or post-myocardial infarction"}]},"trialDetails":[{"nctId":"NCT05942053","phase":"PHASE4","title":"Role of Vitamin K2 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":"Chronic Kidney Diseases","enrollment":44},{"nctId":"NCT05942027","phase":"PHASE4","title":"Role of Coenzyme Q10 in Chronic Kidney Disease","status":"RECRUITING","sponsor":"Tanta University","startDate":"2023-07-15","conditions":"Chronic Kidney Diseases","enrollment":44},{"nctId":"NCT02924727","phase":"PHASE3","title":"Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-12-09","conditions":"Acute Myocardial Infarction","enrollment":5669},{"nctId":"NCT02632747","phase":"PHASE2","title":"Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2016-05-10","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Obesity","enrollment":31},{"nctId":"NCT01856361","phase":"NA","title":"Ramipril for the Treatment of Oligospermia","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2013-07","conditions":"Oligospermia, Teratospermia, Asthenozoospermia","enrollment":2},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT01922141","phase":"PHASE4","title":"Aliskiren Study of Safety and Efficacy in Senior Hypertensives","status":"WITHDRAWN","sponsor":"Novartis Pharmaceuticals","startDate":"2015-05","conditions":"Hypertension","enrollment":""},{"nctId":"NCT00141778","phase":"PHASE2, PHASE3","title":"Renin-angiotensin-aldosterone System (RAAS), Inflammation, and Post-Operative Atrial Fibrillation (AF)","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2005-04","conditions":"Atrial Fibrillation","enrollment":455},{"nctId":"NCT01302899","phase":"PHASE2","title":"To Study the Effects of Aliskiren on Albuminuria and Various Biomarkers in Patients With Nephropathy","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Non-diabetic Nephropathy","enrollment":8},{"nctId":"NCT00923156","phase":"PHASE2","title":"Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2009-05","conditions":"Heart Failure","enrollment":123},{"nctId":"NCT01042392","phase":"PHASE4","title":"Efficacy of Aliskiren Compared to Ramipril in the Treatment of Moderate Systolic Hypertensive Patients","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-11","conditions":"Essential Hypertension","enrollment":506},{"nctId":"NCT00631917","phase":"PHASE4","title":"A Study Evaluating the Gastrointestinal (GI) Safety and Tolerability of Aliskiren Compared to Ramipril in Essential Hypertension","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-02","conditions":"Hypertension","enrollment":774},{"nctId":"NCT00770497","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Ramipril Combination Therapy in Treating Non-diabetic Hypertensive Patients.","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-03","conditions":"Inflammation, Hypertension","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Matching placebo to Ramipril","genericName":"Matching placebo to Ramipril","companyName":"Novartis","companyId":"novartis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a matching placebo formulation designed to mimic Ramipril, an ACE inhibitor that lowers blood pressure by blocking angiotensin-converting enzyme. Used for Clinical trial control for Ramipril studies in hypertension, Clinical trial control for Ramipril studies in heart failure or post-myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}